These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21385847)

  • 1. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
    Waldmann TA; Lugli E; Roederer M; Perera LP; Smedley JV; Macallister RP; Goldman CK; Bryant BR; Decker JM; Fleisher TA; Lane HC; Sneller MC; Kurlander RJ; Kleiner DE; Pletcher JM; Figg WD; Yovandich JL; Creekmore SP
    Blood; 2011 May; 117(18):4787-95. PubMed ID: 21385847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.
    Lugli E; Goldman CK; Perera LP; Smedley J; Pung R; Yovandich JL; Creekmore SP; Waldmann TA; Roederer M
    Blood; 2010 Oct; 116(17):3238-48. PubMed ID: 20631381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-15 in the treatment of cancer.
    Waldmann TA
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1689-701. PubMed ID: 25359408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
    Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.
    Sneller MC; Kopp WC; Engelke KJ; Yovandich JL; Creekmore SP; Waldmann TA; Lane HC
    Blood; 2011 Dec; 118(26):6845-8. PubMed ID: 22067383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
    Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
    Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
    Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
    Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
    Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.
    DeGottardi MQ; Okoye AA; Vaidya M; Talla A; Konfe AL; Reyes MD; Clock JA; Duell DM; Legasse AW; Sabnis A; Park BS; Axthelm MK; Estes JD; Reiman KA; Sekaly RP; Picker LJ
    J Immunol; 2016 Aug; 197(4):1183-98. PubMed ID: 27430715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.
    Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL
    Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques.
    Bergamaschi C; Watson DC; Valentin A; Bear J; Peer CJ; Figg WD; Felber BK; Pavlakis GN
    Cytokine; 2018 Aug; 108():213-224. PubMed ID: 29402721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
    Guo S; Smeltz RB; Nanajian A; Heller R
    Front Immunol; 2020; 11():614667. PubMed ID: 33628206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.
    Rosenthal MA; Dennis D; Liebes L; Furmanski P; Caron D; Garrison L; Wiprovnick J; Peace D; Oratz R; Speyer J; Chachoua A
    J Immunother; 1998 Sep; 21(5):371-8. PubMed ID: 9789199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.